about
ATP13A2 (PARK9) polymorphisms influence the neurotoxic effects of manganeseAtp13a2 expression in the periaqueductal gray is decreased in the Pink1 -/- rat model of Parkinson disease.Copy number variability in Parkinson's disease: assembling the puzzle through a systems biology approachMutations in the ATP13A2 gene and Parkinsonism: a preliminary review.Characterization of cellular protective effects of ATP13A2/PARK9 expression and alterations resulting from pathogenic mutants.Mutation of the parkinsonism gene ATP13A2 causes neuronal ceroid-lipofuscinosisSplicing: is there an alternative contribution to Parkinson's disease?Analysis of ATP13A2 in large neurodegeneration with brain iron accumulation (NBIA) and dystonia-parkinsonism cohorts.Molecular pathogenesis of Parkinson disease: insights from genetic studies.Lack of association between the ATP13A2 A746T variant and Parkinson's disease susceptibility in Han Chinese: a meta-analysis.The role of ATP13A2 in Parkinson's disease: Clinical phenotypes and molecular mechanisms.ATP13A2 variability in Taiwanese Parkinson's disease.A customized high-resolution array-comparative genomic hybridization to explore copy number variations in Parkinson's diseaseThe impact of genetic research on our understanding of Parkinson's diseaseThe role of the Ala746Thr variant in the ATP13A2 gene among Chinese patients with Parkinson's disease.Gender segregation in gene expression and vulnerability to oxidative stress induced injury in ventral mesencephalic cultures of dopamine neurons.Novel mutation in ATP13A2 widens the spectrum of Kufor-Rakeb syndrome (PARK9).
P2860
Q28118761-3CECA502-F690-4DE1-A5A4-C510995D79F7Q30383670-51EA0967-7129-4E30-B8C0-5C746D61ED98Q33364337-50FDA857-D9D8-4376-931A-3BF99ADD9708Q34100399-728A7C91-1033-48EB-B3F4-1BE9DD935D8AQ35795120-2C115EBC-138E-4F0E-A8D3-DF42AD63EC8BQ35997567-5D0DB5D9-9B82-49EB-AFF3-A356739D5F75Q36069844-D1373D85-5E03-40F1-BF0A-7AE5652F6DE3Q36748089-67F66333-334B-4A0B-B45C-F218E56227BAQ37561699-0723539A-502B-4977-AD34-3374740DA114Q38389768-D2C679BC-5EFD-4C27-89F4-6B1882F1B46FQ38434200-570C2E25-0FA8-469F-9CC3-36B0DCF10F03Q39516168-8F49203A-5AD1-491C-827D-9BADF19ED67BQ41482149-20AB035B-50C8-4D52-9D6F-150D7E60A4A9Q41525066-58A10E10-F209-40BD-BFEE-DF11CDD2F289Q41848901-AE148152-FA8B-40F8-805B-F93A475C8433Q48898040-DA5EA7AE-DAB9-4A98-9B9A-AE3719C1EC08Q49140091-A65B98EE-D53E-442C-9216-B4490601A640
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
ATP13A2 variability in Parkinson disease.
@en
ATP13A2 variability in Parkinson disease.
@nl
type
label
ATP13A2 variability in Parkinson disease.
@en
ATP13A2 variability in Parkinson disease.
@nl
altLabel
ATP13A2variability in Parkinson disease
@en
prefLabel
ATP13A2 variability in Parkinson disease.
@en
ATP13A2 variability in Parkinson disease.
@nl
P2093
P2860
P50
P356
P1433
P1476
ATP13A2 variability in Parkinson disease
@en
P2093
Alex Rajput
Alexandra I Soto
Deborah C Mash
Faycal Hentati
Lefkos T Middleton
Mary M Hulihan
Michael G Heckman
Mounir Kefi
Nancy N Diehl
P2860
P304
P356
10.1002/HUMU.20877
P577
2009-03-01T00:00:00Z